X

Drug Profile

NLRP3 inflammasome inhibitor - Biolexis Therapeutics/Halia Therapeutics

Latest Information Update: 26 Aug 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Biolexis Therapeutics; Halia Therapeutics
Class Small molecules
Mechanism of Action NLRP3 protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Research Neurodegenerative disorders

Most Recent Events

31 Jul 2024 Biolexis Therapeutics enters into a collaboration with Halia Therapeutics to develop small molecule NLRP3 inflammasome inhibitor prior to July 2024
31 Jul 2024 Early research in Neurodegenerative disorders in USA (unspecified route) prior to July 2024
31 Jul 2024 Halia Therapeutics plans preclinical studies in Parkinson's disease

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com